Sigma-Aldrich (Merck KGaA, Darmstadt, Germany)

Burlington, Massachusetts, United States (for MilliporeSigma, the U.S. and Canada life science business), with the parent company Merck KGaA headquartered in Darmstadt, Germany. All United States companies → — Founded 1975 (as Sigma-Aldrich through the merger of Sigma Chemical Company and Aldrich Chemical Company; Sigma Chemical Company was founded in 1946 and Aldrich Chemical Company in 1951).

Biotech / Drug Discovery Healthcare Conglomerate Point-of-Care Diagnostics

Acquired — $17 billion (acquired by Merck KGaA in 2015).

Website Claim this company

About Sigma-Aldrich (Merck KGaA, Darmstadt, Germany)

Sigma-Aldrich, operating as part of MilliporeSigma in the U.S. and Canada, is the life science business of Merck KGaA, Darmstadt, Germany. It is a leading supplier to the global life science industry, providing a broad portfolio of over 300,000 products, services, and digital offerings for research, biotechnology development and production, and pharmaceutical drug therapy development and production. The company aims to empower researchers and scientists worldwide with state-of-the-art tools, services, and expertise to facilitate scientific breakthroughs and drive sustainable futures.

For physicians, Sigma-Aldrich (MilliporeSigma) offers critical resources that underpin drug discovery, development, and manufacturing. This includes best-in-class products for pharmaceutical development and manufacturing, along with a fully integrated service organization that supports Contract Development and Manufacturing Organization (CDMO) and contract testing across both traditional and novel modalities. Their offerings are vital for various stages, from early pre-clinical development to licensed production, and encompass areas like raw materials for cell culture products, customized services for raw materials, and manufacturing of active pharmaceutical ingredients. The company is also actively involved in leveraging AI and data-driven solutions to accelerate drug discovery and development, aiming to simplify complex scientific processes and bring new therapies to patients faster.

Focus Areas

Life science technologies specialty chemicals biotechnology pharmaceutical development disease diagnosis genomics proteomics cell biology analytical biochemicals AI drug discovery digital solutions for research

Business Intelligence

Key Investors	Merck KGaA, Darmstadt, Germany (Acquirer)
Partnerships	Siemens (for digital solutions in drug discovery and biomanufacturing), ACD/Labs (for ChemisTwin™ portal)
Acquisitions	Mirus Bio (May 2024), Cell Marque Corporation (2015), BioReliance (2012), JRH Biosciences (2005), Proligo Group (2005), Ultrafine (2004), Tetrionics (2004), Isotec (2001), Genosys Biotechnologies, Inc. (1998), Riedel-de Haën (1997, 1999), Supelco (1993), Fluka (1989), Biomakor (1986)
Technology	Cloud-native deployment (for AIDDISON™ Explorer), AI operating system (integrated into Siemens' Dotmatics Scientific Intelligence Platform), Digital Reference Material Platform (ChemisTwin™ portal)
FDA Clearances	unknown cleared products (estimated)

What Physicians Need to Know

Life Science Technologies & Specialty Chemicals

Sigma-Aldrich, as part of MilliporeSigma (the life science business of Merck KGaA in the US and Canada), offers one of the broadest portfolios in the industry, encompassing over 300,000 products. This includes a vast array of chemicals, reagents, advanced materials, and stable isotopes for chemical synthesis, medicinal chemistry, and materials science. They provide solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

Biotechnology & Pharmaceutical Development

They are a leading supplier to the global Life Science industry, supporting every step of the biotech production chain with a complete end-to-end workflow. Their offerings include products and services for drug discovery, development, and manufacturing, with a focus on both traditional and novel modalities. This includes solutions for high-throughput screening (HTS), bioassays, and structure-activity relationship (SAR) studies, as well as PROTACu00ae degrader building blocks and DNA-Encoded Libraries (DELs).

Disease Diagnosis & Analytical Biochemicals

Sigma-Aldrich provides chromatography products and related tools for various laboratories, including environmental, government, food and beverage, pharmaceutical, biotechnology, medical, and chemical. Their advanced offerings in analytical chromatography, analytical reagents, and reference materials support the complete analytical chemistry workflow, from initial discovery through final validation, ensuring accurate and reproducible results.

Genomics, Proteomics & Cell Biology

The company's portfolio fuels the work of scientists, technicians, and professionals worldwide in discovery solutions. They empower scientists with 3D cell culture models (organoids) to better understand complex tissues and assess drug impact earlier in the development process.

AI Drug Discovery & Digital Solutions for Research

Sigma-Aldrich offers advanced digital solutions leveraging AI to support computational chemists in molecular design, accelerate lead discovery, streamline retrosynthesis, and refine lead compounds. Their AIDDISONu2122 Explorer software uses generative AI for molecular design and candidate prioritization, trained on over 30 years of pharmaceutical R&D data. They also provide SYNTHIAu2122 Retrosynthesis Software for efficient discovery and design of synthetic routes.

Physician Tip

For physicians involved in research or drug development, Sigma-Aldrich (MilliporeSigma) offers a comprehensive ecosystem of products and digital tools. Their AI-powered drug discovery platforms, like AIDDISSONu2122 Explorer, can significantly accelerate early-stage drug discovery by identifying and prioritizing promising molecules based on multi-parameter optimization, including ADMET properties and synthetic feasibility. This can lead to more efficient identification of potential drug candidates and a reduction in the high failure rate of drugs in clinical trials. Additionally, their extensive catalog of high-quality lab materials, reagents, and analytical tools ensures reliable and reproducible results in research and diagnostic settings. The focus on greener products and alternatives also aligns with sustainable research practices.

Sigma-Aldrich's AI tools and software applications, such as AIDDISSONu2122 Explorer and SYNTHIAu2122 Retrosynthesis Software, are designed to complement existing computational and experimental discovery tools. They can export candidate molecules into docking, synthesis planning, and experimental workflows using standard file formats. Furthermore, they are strategically partnering with companies like Siemens to integrate their AI tools and software into platforms like Siemens' Dotmatics Scientific Intelligence Platform, aiming to create connected environments for data-driven decisions and simplified workflows from drug discovery to biomanufacturing.

At a glance

Founded 1975 (as Sigma-Aldrich through the merger of Sigma Chemical Company and Aldrich Chemical Company; Sigma Chemical Company was founded in 1946 and Aldrich Chemical Company in 1951).

HQ Burlington, Massachusetts, United States (for MilliporeSigma, the U.S. and Canada life science business), with the parent company Merck KGaA headquartered in Darmstadt, Germany. · United States

Team size More than 27,000 employees in the Life Science business (MilliporeSigma). The parent company, Merck KGaA, has more than 62,000 employees globally.

CEO Jean-Charles Wirth (CEO of Life Science, Merck KGaA, Darmstadt, Germany).

Funding Acquired — $17 billion (acquired by Merck KGaA in 2015).

FDA clearances unknown (estimated)

Visit site

Products by Sigma-Aldrich (Merck KGaA, Darmstadt, Germany)

No products listed for this company yet. Know of one? Suggest it →

What the Web Says

Sigma-Aldrich, a subsidiary of Merck KGaA, Darmstadt, Germany, is a major supplier of laboratory chemicals and life science products. The company generally receives positive feedback for its wide product selection, product quality, and efficient logistics, especially for academic and research institutions. However, a recurring concern among customers is the high cost of their products compared to competitors. As an employer, reviews indicate a generally positive work environment with good work-life balance and opportunities for learning, though some employees outside of Germany report less visibility for career advancement.

Overall: Mixed

Strengths

Wide selection of products and extensive catalog depth.
High product quality and reliability.
Fast and efficient delivery and logistics.
Good work-life balance for employees.
Supportive and inclusive work environment with opportunities to learn.
Clear and interactive data visualizations in their software (Sigma).

Limitations

Products are often significantly more expensive than competitors.
Customer service can be slow and unhelpful.
Some chemicals may require further purification before use.
Limited customization options and slow performance in their software (Sigma).
Management may not promote employees without a college education.
Employees outside of Germany may have less visibility for career advancement within Merck KGaA.

Based on reviews from: Indeed.com, Reddit, Quora, G2, Capterra, Trustpilot

Last updated: 2026-09-20

Videos

News, demos, and interviews about Sigma-Aldrich (Merck KGaA, Darmstadt, Germany).

Loading videos...

Videos load interactively. If none appear, search YouTube for Sigma-Aldrich (Merck KGaA, Darmstadt, Germany) →

View all on YouTube

Press & Coverage

Sigma-Aldrich (Merck KGaA, Darmstadt, Germany)

Merck Opens BioRelianceu00ae Testing Facility in Darmstadt, Germany to Support Drug Product Release in Europe

Merck has opened a new u20ac25 million BioRelianceu00ae testing facility in Darmstadt, Germany, to expand commercial drug substance and drug product release testing and stability studies for biopharmaceutical companies in Europe. This facility aims to meet the growing demand for biologics testing and support customers from drug development through commercialization.

2026-07

Sigma-Aldrich (Merck KGaA, Darmstadt, Germany)

Merck Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets

Merck KGaA, Darmstadt, Germany, has agreed to acquire Bio-Techne for US$73 per share in cash, representing an enterprise value of US$11.3 billion (EUR 9.9 billion), to strengthen its leadership in the life sciences market. This acquisition is expected to enhance Merck's position in fast-growing segments.

2026-06

Sigma-Aldrich (Merck KGaA, Darmstadt, Germany)

Merck KGaA, Darmstadt, Germany and Siemens Deepen Strategic Partnership to Accelerate AI and Data-Driven Drug Discovery and Development

Merck KGaA, Darmstadt, Germany, and Siemens have signed a new Memorandum of Understanding (MoU) to extend their strategic partnership, focusing on accelerating digital transformation in the life science industry through integrated software solutions, systems, and consumables that leverage automation, data, and AI.

2025-09

Sigma-Aldrich (Merck KGaA, Darmstadt, Germany)

Merck Opens Climate-Neutral u20ac150 Million Filter Manufacturing Facility in Ireland

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced the opening of its first climate-neutral manufacturing facility in Ireland, a u20ac150 million investment that creates over 200 jobs in filter production.

2025-07

Sigma-Aldrich (Merck KGaA, Darmstadt, Germany)

Merck Announces u20ac 62 Million Investment in New Quality Control Facility in Darmstadt, Germany

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is investing u20ac62 million in a new quality control building at its Darmstadt headquarters, scheduled for completion by mid-2025. This facility will consolidate 135 employees and various functions into a single, state-of-the-art space.

2024-06

Sigma-Aldrich (Merck KGaA, Darmstadt, Germany)

Merck Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing

Merck has signed a definitive agreement to acquire Mirus Bio for US$600 million, aiming to strengthen its position as a leading supplier for viral vector manufacturing. This acquisition will enhance Merck's offerings in the life science sector.

2024-05

Merck KGaA, Darmstadt, Germany

2026 Research Grants

Merck KGaA, Darmstadt, Germany, is offering research grants in 2026 for innovative research in areas such as in-vitro models for neuroinflammatory diseases and artificial intelligence in cell culture media and process development, with grants up to u20ac250,000 per year for up to three years.

2026

Sigma-Aldrich (Merck KGaA, Darmstadt, Germany)

Regulatory Information

Sigma-Aldrich provides regulatory expertise and solutions to help customers navigate evolving regulatory landscapes in the life science industry, including guidance on GMPs for ATMPs, USP <665> for single-use systems, and compliance for food and beverage testing.

unknown

Frequently Asked Questions

What life science technologies and products does Sigma-Aldrich (Merck KGaA, Darmstadt, Germany) offer that are relevant to pharmaceutical development and disease diagnosis?

Sigma-Aldrich, as part of Merck KGaA, Darmstadt, Germany, provides a comprehensive portfolio of life science technologies crucial for pharmaceutical development and disease diagnosis. This includes a wide range of products for genomics, proteomics, and cell biology research, such as reagents, kits, and instruments for gene editing, protein analysis, and cell culture. Their offerings support various stages from basic research to clinical applications, aiding in the identification of biomarkers and development of new therapeutic strategies.

How does Sigma-Aldrich support biotechnology and AI drug discovery initiatives, and what digital solutions do they provide for research?

Sigma-Aldrich supports biotechnology and AI drug discovery through its extensive catalog of specialty chemicals and advanced analytical biochemicals, which are essential building blocks for novel drug compounds and high-throughput screening. They also offer digital solutions designed to streamline research workflows, including platforms for data management, analysis, and experimental design, which can accelerate the drug discovery process and facilitate AI-driven research.

What is Sigma-Aldrich's stance on compliance and regulatory standards for their products used in healthcare and pharmaceutical settings?

Sigma-Aldrich is committed to upholding stringent compliance and regulatory standards for all its products, particularly those used in healthcare and pharmaceutical settings. They adhere to international quality management systems and provide extensive documentation and support to ensure their products meet the necessary regulatory requirements, such as those from the FDA and EMA, which is critical for clinical and diagnostic applications.

Can you elaborate on Sigma-Aldrich's pricing models and support services for large-scale research institutions and pharmaceutical companies?

Sigma-Aldrich offers flexible pricing models, including bulk discounts and customized agreements, to accommodate the needs of large-scale research institutions and pharmaceutical companies. Their support services are robust, featuring dedicated technical support, field application scientists, and customer service teams to assist with product selection, troubleshooting, and experimental optimization, ensuring seamless integration of their products into complex research environments.

What kind of partnerships does Sigma-Aldrich (Merck KGaA, Darmstadt, Germany) engage in to advance life science research and healthcare solutions?

Sigma-Aldrich, as part of Merck KGaA, Darmstadt, Germany, actively engages in strategic partnerships with academic institutions, biotechnology firms, and pharmaceutical companies globally. These collaborations aim to accelerate scientific discovery, co-develop innovative technologies, and bring new healthcare solutions to market, leveraging their expertise in life science tools and specialty chemicals to address unmet medical needs.

Given that Sigma-Aldrich is part of Merck KGaA, Darmstadt, Germany, how does this relationship impact the company's stability and long-term commitment to the life science sector?

Being a part of Merck KGaA, Darmstadt, Germany, significantly enhances Sigma-Aldrich's stability and long-term commitment to the life science sector. This integration provides access to substantial resources, a broader global network, and a shared vision for innovation in healthcare and research. This backing ensures continuous investment in R&D, robust supply chains, and sustained support for their customers in the ever-evolving scientific landscape.

Related Companies

Suggest an Edit →